Owens & Minor reported a solid Q2 with revenue growth driven by elective procedures and PPE sales. The company's strategic focus on culture, discipline, and investment continues to support long-term growth initiatives. Expansion in manufacturing capabilities, product portfolio diversification, and investments in technology and distribution infrastructure are expected to provide attractive returns. Owens & Minor maintains a strong balance sheet with low leverage, allowing for continued investments and operational flexibility. Despite inflationary pressures and supply chain issues, the company reaffirms its 2021 and 2022 guidance. The second half of the year is expected to see improved cash flow and a shift in profitability towards Q4 due to seasonal healthcare utilization. Owens & Minor remains optimistic about its long-term prospects, leveraging its strong value chain, scalability, and customer-centric approach to advance healthcare solutions.